Skip to main content

MRKR

Stock
Health Care
Biotechnology

Performance overview

MRKR Price
Price Chart

Forward-looking statistics

Beta
0.87
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Company info

SectorHealth Care
IndustryBiotechnology
Employees5
Market cap$30.9M

Fundamentals

Enterprise value$3.6M
Revenue$5.7M
Revenue per employee
Profit margin-224.44%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.32
Dividend per share
Revenue per share$0.60
Avg trading volume (30 day)$329K
Avg trading volume (10 day)$92K
Put-call ratio

Macro factor sensitivity

Growth+1.4
Credit+4.0
Liquidity+2.6
Inflation-4.2
Commodities+0.7
Interest Rates-0.4

Valuation

Dividend yield0.00%
PEG Ratio-1.10
Price to sales3.18
P/E Ratio-1.10
Enterprise Value to Revenue0.64
Price to book1.24

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day
Ex. dividend day

News

MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022.

Zacks Investment Research (November 10, 2022)
Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1. The company reported initial results from the Phase 2 trial for MT-401 as a treatment option for Acute myeloid leukemia (AML) in the post-transplant setting.

Benzinga (February 17, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free